Enhanced Antifungal Therapy to Improve Survival in Early Disseminated Cryptococcal Infection
加强抗真菌治疗可提高早期播散性隐球菌感染的生存率
基本信息
- 批准号:10621009
- 负责人:
- 金额:$ 67.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-21 至 2028-03-31
- 项目状态:未结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAdultAfricaAfrica South of the SaharaAmphotericinAmphotericin BAntifungal AgentsAntifungal TherapyAntigensBloodCD4 Lymphocyte CountCause of DeathCellsCentral Nervous System InfectionsCessation of lifeClinical TrialsCost AnalysisCountryCryptococcal MeningitisCryptococcosisCryptococcusDataData ReportingDevelopmentDiseaseDoseEnrollmentExcess MortalityFluconazoleFlucytosineGuidelinesHIVHIV therapyHospital CostsIncidenceIncomeInfectionInternationalLiposomesMeningitisNeurocognitiveNeurologicNeurological outcomeOutcomeParticipantPerformancePersonsPhasePlasmaPreventionProspective, cohort studyPublic HealthRandomizedRecommendationRegimenTestingUgandaWorkWorld Health Organizationantiretroviral therapybrain parenchymacomparative effectiveness trialcostcost effectivecost effective interventioncost-effectiveness evaluationdisabilityeffective therapyefficacy evaluationefficacy testinghigh riskimprovedmortalityphase III trialpreventrandomized trialrandomized, clinical trialsrecruitsafety and feasibilityscreeningstandard of caresurvival outcometreatment guidelines
项目摘要
Abstract
Cryptococcal meningitis is the most common adult neuroinfection in sub-Saharan Africa and causes ~15%
of AIDS-related mortality globally. In the weeks prior to onset of meningitis, cryptococcal antigen (CrAg) is
detectable in the blood, and is a predictor of meningitis and death. CrAg screening in plasma is an effective
public health strategy to identify persons with CD4<200 cells/mcL at high risk of meningitis and death. In a
randomized trial of 2000 persons with HIV, CrAg screening and preemptive fluconazole treatment yielded a
28% survival benefit over standard-of-care. As a result, the World Health Organization and U.S. guidelines
recommend CrAg screening. Yet despite the survival benefit seen with CrAg screening and preemptive
therapy, 25% of initially asymptomatic CrAg+ persons treated with fluconazole still die, even with HIV therapy.
From 4 prospective cohort studies of CrAg+ persons in Africa, we have determined that as plasma CrAg
titer increases, mortality increases, despite fluconazole therapy. Among asymptomatic CrAg+ persons,
disseminated cryptococcosis is the most commonly identified cause of death. We posit that subclinical
disseminated early neuroinfection in the brain parenchyma accompanies high CrAg titers, and fluconazole is
inadequate therapy. More effective treatment is critically needed to reduce mortality in CrAg+ persons.
For symptomatic cryptococcal meningitis, amphotericin B is the most effective antifungal; fluconazole alone
is inadequate. Recent randomized trial data reported single dose of liposomal amphotericin (AmBisome) 10 mg
/kg with flucytosine (5FC) and fluconazole is as effective and less toxic than the traditional 7-day amphotericin
+ 5FC for meningitis. We hypothesize that AmBisome (10mg/kg x1), when combined with fluconazole, will be
more effective than fluconazole monotherapy for asymptomatic CrAg+ persons. We have enrolled 244 CrAg+
persons in the initial phase II of a phase II/III randomized trial to demonstrate safety and feasibility of this
enhanced regimen in Uganda, and now we seek to complete the phase III trial in order to test efficacy.
The objective of this application is to assess the efficacy of AmBisome plus fluconazole to prevent
cryptococcal meningitis and death. We will complete a randomized clinical trial of 600 CrAg+ persons (i.e. 356
more participants) to determine if preemptive therapy with AmBisome (10mg/kg x1) plus fluconazole for CrAg+
persons will improve cryptococcal meningitis-free 6-month survival compared with the current standard of
fluconazole monotherapy (Aim 1). In Aim 2, we will determine if neurocognitive outcomes in CrAg+ persons
preemptively treated with AmBisome with fluconazole are superior to outcomes with fluconazole monotherapy.
Finally, in Aim 3 we will evaluate the cost and cost-effectiveness of AmBisome with fluconazole preemptive
treatment in CrAg+ persons. Findings from this trial will impact U.S. and international HIV guidelines on the
optimal prevention of cryptococcal meningitis, in order to reduce mortality in persons living with HIV.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Radha Rajasingham其他文献
Radha Rajasingham的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Radha Rajasingham', 18)}}的其他基金
An Enhanced Package of Care to Reduce Mortality in Persons with Advanced HIV Disease
加强一揽子护理以降低晚期艾滋病毒患者的死亡率
- 批准号:
10473887 - 财政年份:2021
- 资助金额:
$ 67.69万 - 项目类别:
An Enhanced Package of Care to Reduce Mortality in Persons with Advanced HIV Disease
加强一揽子护理以降低晚期艾滋病毒患者的死亡率
- 批准号:
10322279 - 财政年份:2021
- 资助金额:
$ 67.69万 - 项目类别:
An Enhanced Package of Care to Reduce Mortality in Persons with Advanced HIV Disease
加强一揽子护理以降低晚期艾滋病毒患者的死亡率
- 批准号:
10673693 - 财政年份:2021
- 资助金额:
$ 67.69万 - 项目类别:
Evaluation of CRAG screening with enhanced antifungal therapy for asymptomatic CRAG-positive persons
对无症状 CRAG 阳性者进行强化抗真菌治疗的 CRAG 筛查评估
- 批准号:
10341089 - 财政年份:2018
- 资助金额:
$ 67.69万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 67.69万 - 项目类别:
Research Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 67.69万 - 项目类别:
Standard Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 67.69万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 67.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 67.69万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 67.69万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 67.69万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 67.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 67.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 67.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)